Drugs / ABO1105
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07289503 | May → Sep 2025 overdue | respiratory syncytial virus infectious disease | Suzhou Abogen Biosciences Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07289542 | Sep 2025 → Jan 2026 overdue | respiratory syncytial virus infectious disease | Suzhou Abogen Biosciences Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABO1105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07289503 ↗ |